Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer

• Hung-Yang Kuo,
• Jhe-Cyuan Guo,
• Chih-Hung Hsu

Affiliations

Hung-Yang Kuo

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan

Jhe-Cyuan Guo

Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Chih-Hung Hsu

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; Corresponding author. Department of Oncology, National Taiwan University Hospital, Graduate Institute of Oncology, National Taiwan University College of Medicine, No.7, Chung Shan S. Rd., Zhongzheng Dist., Taipei 100225, Taiwan. Fax: +886 2 23711174.